卡波扎尼布
医学
肝细胞癌
安慰剂
内科学
肿瘤科
酪氨酸激酶抑制剂
血管内皮生长因子
酪氨酸激酶
索拉非尼
癌
血管内皮生长因子受体
癌症
受体
病理
替代医学
作者
Ghassan K. Abou‐Alfa,Tim Meyer,Ann‐Lii Cheng,Anthony B. El-Khoueiry,Lorenza Rimassa,Baek‐Yeol Ryoo,İrfan Çiçin,Philippe Merle,Yen-Hsun Chen,Joong‐Won Park,Jean-Frederic Blanc,Luigi Bolondi,Heinz‐Josef Klümpen,Stephen L. Chan,Vittorina Zagonel,Tiziana Pressiani,Min-Hee Ryu,Alan P. Venook,Colin Hessel,Anne E. Borgman-Hagey,Gisela Schwab,Robin Kate Kelley
标识
DOI:10.1056/nejmoa1717002
摘要
Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of hepatocellular carcinoma and the development of resistance to sorafenib, the standard initial treatment for advanced disease. This randomized, double-blind, phase 3 trial evaluated cabozantinib as compared with placebo in previously treated patients with advanced hepatocellular carcinoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI